Empagliflozin's CV Benefit Impresses At EASD, But What Will FDA Say?
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer/Lilly's Jardiance delivers impressive CV death benefit but no effect on myocardial infarction or stroke – prompting questions about relevance of MACE composite primary endpoint.
You may also be interested in...
Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure
ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.
FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change
FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.
At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
If cardiovascular studies are required for non-cardiac drugs, they should be focused on specific signals of heart-related concern that may not include ischemic events, advisory committee cardiologists say during review of Novo Nordisk’s Saxenda for obesity.